U.S. Markets closed

See what the IHS Markit Score report has to say about Pfizer Inc.

IHS Markit

Pfizer Inc

NYSE:PFE

Score: Positive (87)

26 days at current score.

Upgraded from Neutral on October 26th 2017

View full report here!

Summary


  • This company ranked positively compared to the Healthcare sector despite only 2 positive IHS Markit Categories
  • Perception of the company's creditworthiness is positive
  • ETFs holding this stock are seeing positive inflows but are weakening
  • Bearish sentiment is low


Bearish sentiment

Short interest | Positive

Short interest is extremely low for PFE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE.

Money flow

ETF/Index ownership | Negative

ETF activity is negative and may be weakening. The net inflows of $4.98 billion over the last one-month into ETFs that hold PFE are among the lowest of the last year and appear to be slowing.

Economic sentiment

PMI by IHS Markit | Neutral

According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however.

Credit worthiness

Credit default swap | Positive

The current level displays a positive indicator. PFE credit default swap spreads are near the lowest level of the last one year and indicate improvement in the market's perception of the company's credit worthiness.

Please send all inquiries related to the report to score@ihsmarkit.com.

Charts and report PDFs will only be available for 30 days after publishing.

This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.